PP405 is a new hair growth stimulant different from Minoxidil, currently in phase 2 trials. Users discuss its potential, safety concerns, and the long wait before it might be available.
PP405 is a new drug in Phase 2 trials for hair loss, generating cautious optimism among users. Some users are currently using finasteride and experiencing side effects, while others are skeptical about unapproved products being sold.
A recent discovery in hair cloning identified a previously unknown cell type essential for hair follicle growth, which could potentially make lab-grown hair viable if translated to humans. However, skepticism remains due to past delays and the challenges of replicating results in humans and making the process affordable.
User shared 8-month hair loss treatment progress using topical fin/min, topical dut, mk677, RU, and microneedling. They experienced watery semen as a side effect but saw significant improvement in hair growth.
TDM-105795 showed better efficacy and safety in trials for hair loss, with a higher hair count improvement compared to GT20029 and HMI 115, but it's not as widely discussed. The user is questioning why this is the case.
A user is considering a $5,295 one-year hair loss program from HairClub/Bosley, which includes treatments like finasteride, minoxidil, and a DNA test to personalize treatment. Opinions are mixed, with some suggesting cheaper alternatives like standard medications and questioning the value of the program.
A topical solution called "Multi-Peptide Serum for Hair Density" by The Ordinary Company, which contains several ingredients that are used in alternatives to Minoxidil and was found to have better results than 5% Minoxidil in a study. People who have tried it shared their experiences with the serum as well.
FOL-005 claims to be more effective than Minoxidil and Finasteride but lacks anti-DHT properties, leading to potential reduced efficacy over time. Concerns are raised about misleading marketing and the safety of alternative treatments like Pyrilutamide and Clascoterone.
Hair loss is linked to DHT, with treatments like finasteride and minoxidil being common but not definitive. Economic interests influence research, and there is potential for new treatments like PP405 and RU58841.
A new topical Dutasteride with 20 times better scalp absorption being developed and tested for release in 2023; use of existing drugs, such as Minoxidil and finasteride; and mesotherapy as an alternative hair loss treatment.
A 21-year-old male diagnosed with telogen effluvium and male pattern baldness started oral finasteride, which initially slowed hair loss and slightly thickened hair, but experienced increased shedding after surgery. The doctor recommended iron and vitamin D supplements, and the user is seeking additional advice.
The conversation discusses GT20029, a new topical drug for hair loss and acne without notable side effects, which has been accepted for investigational use in China. Some users express skepticism about the legitimacy of the company and the potential for other drugs like RU58841 to be developed due to patent expiration and lack of profitability.
The conversation is about the difference in hair loss between bodybuilders in the "Golden Era" and modern bodybuilders. Some users speculate that factors such as the types and doses of steroids used, genetics, diet, microplastics, and overall health may contribute to hair loss. Hair loss prevention medication and transplants are mentioned as potential treatments.
The user is experiencing progressive hair thinning despite using finasteride and dutasteride. A biopsy confirmed male pattern baldness, and minoxidil was suggested as an additional treatment.
Hair loss discussion involves PRP (platelet rich plasma) treatment. PRP doesn't stop hair loss, only promotes regrowth; minoxidil is suggested as a better alternative.
User tried oral finasteride, topical finasteride, topical dutasteride, and RU58841 but experienced side effects. They discuss upcoming treatments like clascoterone, pyrilutamide, gt20029, and KY19382 as potential options.
Exosomes are being considered for hair regrowth, with some users reporting initial improvement. One user moved on to using dutasteride and oral minoxidil with positive results.
The progress of Phase I of HMI-115, a potential hair loss treatment, which consists of Minoxidil, finasteride, and RU58841. The estimated completion date is June.
PP405 shows promise for reactivating hair follicles, with potential maintenance using 5AR inhibitors. Current treatments like Minoxidil and finasteride are effective but have limitations, and there is hope for more effective solutions in the future.
PP405 is expected to be a promising addition to hair loss treatments, potentially working well with existing treatments like finasteride and minoxidil, but not as a standalone solution. Users are hopeful for its effectiveness, especially in combination with other treatments, though expectations vary.
The conversation is about organizing hair regrowth results using a standard format in a single post for easier access. Treatments mentioned include oral minoxidil, oral finasteride, and dermarolling.
The conversation discusses using minoxidil, finasteride, a dermastamp, and botanical oils like peppermint, rosemary, and pumpkin seed oil for hair growth. The user is considering using Alpha Infuse, which combines microneedling with plant oils, to enhance results.
RootBioTec, a basil hairy root extract, claims to reduce hair loss by 31% in two months by inhibiting 5α reductase II and stimulating hair follicles. There is limited independent information available about its effectiveness.
Concerns about metal particles from dermapen or dermaroller needles potentially entering the skin and lymph nodes, similar to tattoo needles. Discussion includes the possibility of using Minoxidil, finasteride, and RU58841 for hair loss treatment.
A human trial involving the use of Verteporfin as a treatment for hair loss, which has been ongoing for 119 days with an update on its progress. Treatments such as Minoxidil, Finasteride and RU58841 have also been discussed.